Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder

References

• Baldwin J. Veterans Treatment Courts: Studying Dissemination, Implementation, and Impact of Treatment-Oriented Criminal Courts. Gainesville, FL: University of Florida; 2013.
   Google Scholar
• Tsai J, Flatley B, Kasprow WJ, Clark S, Finlay A. Diversion of veterans with criminal justice involvement to treatment courts: participant characteristics and outcomes. Psychiatr Serv. 2017;68(4):375–383.
   PubMed Web of Science ®Google Scholar
• Douglas Marlowe CH, Fox C. Painting the Current Picture: A National Report on Drug Courts and Other Problem-Solving Courts in the United States. Alexandria, VA: National Drug Court Institute; 2016.
   Google Scholar
• Center for Children and Family Futures and National Association of Drug Court Professionals. Family Treatment Court Best Practice Standards. Center for Children and Family Futures and National Association of Drug Court Professionals; 2019. Supported by Grant #2016-DC-BX-K003 awarded by the Office of Juvenile Justice and Delinquency Prevention, Office of Justice Programs, U.S. Department of Justice, Lake Forest, CA.
   Google Scholar
• Dodd EA. Mental Health Courts: A Guide to Research-Informed Policy and Practice. New York, NY: Council of State Governments Justice Center; 2009.
   Google Scholar
• National Academies of Science Engineering & Medicine. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies Press; 2019.
   Google Scholar
• Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Netw Open. 2020;3(2):e1920622.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137–145.
   PubMed Web of Science ®Google Scholar
• Potter JS, Marino EN, Hillhouse MP, et al. Buprenorphine/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from Starting Treatment With Agonist Replacement Therapies (START). J Stud Alcohol Drugs. 2013;74(4):605–613.
   PubMed Web of Science ®Google Scholar
• Nielsen S, Larance B, Lintzeris N, et al. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev. 2016;5(5):CD011117.
   PubMed Web of Science ®Google Scholar
• Krawczyk N, Picher CE, Feder KA, Saloner B. Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine. Health Aff (Millwood). 2017;36(12):2046–2053.
   PubMed Web of Science ®Google Scholar
• Yatsco AJ, Garza RD, Champagne-Langabeer T, Langabeer JR. Alternatives to arrest for illicit opioid use: a joint criminal justice and healthcare treatment collaboration. Subst Abuse. 2020;14:1178221820953390.
   Web of Science ®Google Scholar
• Fendrich M, LeBel TP. Implementing access to medication assisted treatment in a drug treatment court: correlates, consequences, and obstacles. J Offender Rehabil. 2019;58(3):178–198.
   Web of Science ®Google Scholar
• Friedmann PD, Hoskinson R, Gordon M, et al. Medication-assisted treatment in criminal justice agencies affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012;33(1):9–18.
   PubMed Web of Science ®Google Scholar
• Physicians for Human Rights. Neither Justice nor Treatment: Drug Courts in the United States. New York, NY: Physicians for Human Rights; 2017.
   Google Scholar
• National Association of Drug Court Professionals. Adult Drug Court Best Practice Standards Volume II National Association of Drug Court Professionals. Alexandria, VA: National Association of Drug Court Professionals; 2015.
   Google Scholar
• Andraka-Christou B, Atkins DN. Whose opinion matters about medications for opioid use disorder? A cross-sectional survey of social norms among court staff. Subst Abus. 2020:1–16.
   PubMed Web of Science ®Google Scholar
• Matusow H, Dickman SL, Rich JD, et al. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44(5):473–480.
   PubMed Web of Science ®Google Scholar
• Csete J, Catania H. Methadone treatment providers' views of drug court policy and practice: a case study of New York State. Harm Reduct J. 2013;10(:35.
   PubMed Web of Science ®Google Scholar
• Andraka-Christou B. What is treatment for opioid addiction in problem-solving courts? A study of 20 Indiana drug & veterans courts. CRCL. 2017;13:189–254.
   Google Scholar
• U.S. Bureau of Justice Assistance. Medication-assisted Treatment. https://bja.ojp.gov/sites/g/files/xyckuh186/files/media/document/adc-faq-medication-assisted-treatment.pdf
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Grants to Expand Substance Abuse Treatment Capacity in Adult and Family Treatment Drug Courts: Funding Opportunity Announcement (FOA) No. TI-20-003. Rockville, MD: Substance Abuse & Mental Health Services Administration; 2020.
   Google Scholar
• Andraka-Christou B, Atkins D. Beliefs about medications for opioid use disorder among Florida criminal problem-solving court & dependency court staff. Am J Drug Alcohol Abuse. 2020;46(6):749–760.
   PubMed Web of Science ®Google Scholar
• Andraka-Christou B, Gabriel M, Madeira J, Silverman RD. Court personnel attitudes towards medication-assisted treatment: a state-wide survey. Journal of Substance Abuse Treatment. 2019;104:72–82.
   PubMed Web of Science ®Google Scholar
• Smith v. Aroostook, No. 1:18-cv-352-NT (D. Me. Mar. 27, 2019).
   Google Scholar
• Smith v. Aroostook, No. 1:18 cv 352 NT (D. Me. Mar. 27, 2019), aff’d, No. 19 1340, (1st Cir. Apr. 30).
   Google Scholar
• Qualtrics Experience Management Platform [computer program]. Version 1.3. Provo, Utah; 2018.
   Google Scholar
• Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90–96.
   PubMed Web of Science ®Google Scholar
• Sullivan MA, Bisaga A, Pavlicova M, et al. A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry. 2019;176(2):129–137.
   PubMed Web of Science ®Google Scholar
• Willis GB. Cognitive Interviewing: A Tool for Improving Questionnaire Design. Thousand Oaks, CA: Sage Publications; 2005.
   Google Scholar
• Andraka-Christou B, Atkins D, Madeira J, Silverman RD. Receipt of training about medication for opioid use disorder from pharmaceutical manufacturers: a preliminary study of Florida criminal problem-solving and dependency court staff. Drug Alcohol Rev. 2020;39(5):583–587.
   PubMed Web of Science ®Google Scholar
• Sloan FA, Gifford EJ, Eldred LM, Acquah KF, Blevins CE. Do specialty courts achieve better outcomes for children in foster care than general courts? Eval Rev. 2013;37(1):3–34.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series 63. Full Document. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.
   Google Scholar
• Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2–5 years. Am J Addict. 2008;17(2):116–120.
   PubMed Web of Science ®Google Scholar
• Lo-Ciganic WH, Donohue JM, Kim JY, et al. Adherence trajectories of buprenorphine therapy among pregnant women in a large state Medicaid program in the United States. Pharmacoepidemiol Drug Saf. 2019;28(1):80–89.
   PubMed Web of Science ®Google Scholar
• Lo-Ciganic WH, Gellad WF, Gordon AJ, et al. Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction. 2016;111(5):892–902.
   PubMed Web of Science ®Google Scholar
• Potter JS, Dreifuss JA, Marino EN, et al. The multi-site prescription opioid addiction treatment study: 18-month outcomes. J Subst Abuse Treat. 2015;48(1):62–69.
   PubMed Web of Science ®Google Scholar
• National Association of Drug Court Professionals. Adult Drug Court Best Practice Standards Volume I Text Revision. Alexandria, VA: National Association of Drug Court Professionals; 2018.
   Google Scholar
• Champagne-Langabeer T, Swank MW, Langabeer JR. 2nd. Routes of non-traditional entry into buprenorphine treatment programs. Subst Abuse Treat Prev Policy. 2020;15(1):6.
   PubMed Web of Science ®Google Scholar
• Hanna J, Kubiak S, Pasman E, et al. Evaluating the implementation of a prisoner re-entry initiative for individuals with opioid use and mental health disorders: application of the consolidated framework for implementation research in a cross-system initiative. J Subst Abuse Treat. 2020;108:104–101.
   PubMed Web of Science ®Google Scholar
• Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405–403.
   PubMed Web of Science ®Google Scholar
• Mitchell SG, Willet J, Monico LB, et al. Community correctional agents' views of medication-assisted treatment: examining their influence on treatment referrals and community supervision practices. Subst Abus. 2016;37(1):127–133.
   PubMed Web of Science ®Google Scholar
• McKenzie MN, Zaller N, Bazazi A, Rich J. Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. J Opioid Manag. 2010;5:219–227.
   Google Scholar
• Friedmann PD, Wilson D, Knudsen HK, et al. Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections. J Subst Abuse Treat. 2015;50:50–58.
   PubMed Web of Science ®Google Scholar